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Objective: To obtain epidemiological data on Traditional Chinese Medicine (TCM) therapeutic status of acute 
myocardial infarction (AMI) and to determine TCM characteristics and advantages to improve the level of TCM 
prevention and treatment of AMI.  
Methods: Clinical epidemiology methods were used to register and survey the TCM therapeutic status of 
hospitalized AMI patients. In 2001, the Chinese Association of Integrative Medicine surveyed the therapeutic status 
of 3308 AMI patients hospitalized in 30 hospitals in Beijing and Shanghai from 2000–2001. The Beijing 
Collaborative Study Group on Therapeutic Status of Acute Myocardial Infarction (the Study Group) then conducted 
a 10-year-long register survey on hospitalized AMI patients in Third-grade A-Level TCM hospitals in Beijing. After 
2002, the Study Group further surveyed the treatment conditions of AMI-hospitalized patients in 10 Second-grade 
A-Level TCM hospitals. The therapeutic status in 8 Third-grade A-Level Western medicine hospitals was surveyed 
in 2001 and 2005 as a control. In 2008, in cooperation with the China Association of Chinese Medicine, the Study 
Group further performed a survey at 26 Third-grade A-Level TCM hospitals nation-wide. Approximately 5000 
cases were investigated to obtain authoritative data on the therapeutic status of AMI patients in TCM hospitals in 
China.
Results: We found that Chinese herbal intravenous preparations may be beneficial in reducing the mortality of AMI. 
Major complications of AMI, such as heart failure and arrhythmia, were significantly less during the 10-year survey 
period. The mortality of hospitalized AMI patients showed a decline. TCM treatment was helpful for AMI patients 
in improving their quality of life. Ten-year dynamic monitoring showed that the ability to perform reperfusion and 
to use drugs appropriately, as well as an effort to carry out the Clinical Guidelines has made great progress in TCM 
hospitals. However, TCM hospitals still have some problems in treating AMI, including a lack of standardized TCM 
syndrome diagnosis, the need for syndrome differentiation and treatment standardization, and clinical skills in 
reperfusion and standardized drug treatment still need to be further improved. Compared with AMI patients in 
Western medicine hospitals during the same period, those in TCM hospitals had the following characteristics: they 
were admitted to hospital later; they were older when they had a heart attack; there were more females, they had 
more problems in their medical history, and they had more concomitant illnesses and complications. Therefore, the 
demographic baseline data were significantly different between AMI patients in TCM hospitals and those in 
Western medicine hospitals. This indicated that patients in TCM hospitals were more critical than those in Western 
medicine hospitals. 
Conclusions: TCM has special advantages in treating AMI. TCM hospitals are making continuous progress in 
standardized treatment of AMI, but further improvement is still required. AMI patients in TCM hospitals have some 
special characteristics, and their condition may be more critical. Further clinical research on TCM treatment of AMI 
is required. 
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With the process of aging, cardiovascular diseases have 
become the leading cause of death. Acute myocardial 
infarction (AMI) is the most common cardiovascular 
intensive illness. Although cardiovascular diseases are 
always the primary topic in the strategy for the 
development of Chinese medicine, there are insufficient 
epidemiological data on Chinese medicine treatment of 
AMI in the past 60 years, and well designed clinical 
studies on Chinese medicine treatment of AMI are also 
rare. 
From the early 1970s to early 1990s, in-hospital 
mortality in AMI patients in Beijing gradually decreased 
from 23.20% to 10.8%.1-3 Surveys in Tianjin, Shanghai 
and Guangzhou  showed that the mortality from AMI is 
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between 12% and 20%.4-6 Since 2000, several large-scale 
clinical epidemiological surveys on coronary heart 
disease have been launched in China, including the 
Survey on the Treatment Status of AMI (STSAMI), the 
Global Registry of Acute Coronary Events (GRACE), 
the Clinical Pathways for Acute Coronary Syndrome in 
China (CPACS) and Bridging the Gap on CAD 
Secondary Prevention (BRIG). Each of these studies 
investigated at least 3000 cases. STSAMI was the only 
clinical epidemiological study on AMI.7
STSAMI, which was initiated by the Chinese 
Association of Integrative Medicine, Committee of 
Cardiovascular Diseases, involved 3308 hospitalized 
AMI cases in 30 hospitals in Beijing and Shanghai 
during the period of 2000–2001.8,9 The Beijing 
Collaborative Study Group on Therapeutic Status of 
Acute Myocardial Infarction (the Study Group) then 
conducted a 10-year long register survey on hospitalized 
AMI patients in Third-grade A-Level TCM hospitals in 
the Beijing area. After 2002, the Study Group further 
investigated the treatment conditions of AMI 
hospitalized patients in 10 Second-grade A-Level TCM 
hospitals. The therapeutic status in 8 Third-grade 
A-Level Western medicine hospitals was surveyed in 
2001 and 2005 as a control. In 2008, in cooperation with 
the China Association of Chinese Medicine, the Study 
Group further carried out a survey at 26 Third-grade 
A-Level TCM hospitals nation-wide, and approximately 
5000 cases were investigated. To date, the Study Group 
has obtained the most authoritative data on the 
therapeutic status of AMI patients in TCM hospitals in 
China. The related survey results will be published 
gradually. Preliminary survey results showed that TCM 
has special advantages in treating AMI, and TCM 
hospitals have made continuous progress in the treatment 
standardization for AMI, but there are still some 
problems. It was also found that AMI patients in TCM 
hospitals have some special characteristics.  
TCM has particular advantages in treating AMI 
Mortality is a strong end point in clinical studies on 
cardiovascular diseases. Our survey showed that Chinese 
herbal intravenous preparations may be beneficial in 
reducing the mortality of AMI. Results from a logistic 
multiple regression analysis on mortality in 12 TCM or 
Western medicine hospitals in 2000 showed that TCM 
intravenous preparations ranked as the third contributor 
in reducing mortality.8 Surveys on both 1390 in-hospital 
AMI patients from 16 Second-grade or Third-grade TCM 
hospitals in 2002–2005 and 1663 hospitalized AMI 
patients from 13 Third-grade A-Level TCM hospitals or 
Western medicine hospitals obtained the same results.10,11
Logistics regression analysis on 10-year clinical data and 
mortality of AMI patients from Third-grade A-Level 
TCM hospitals in the Beijing area during 1999–2008 
also showed that TCM intravenous preparations were 
effective in lowering the mortality rate of AMI. Statistics 
data on AMI in Third-grade A-Level TCM Hospitals in 
Beijing showed that the major complications of AMI, 
such as heart failure and arrhythmia, were significantly 
less during these 10 years. The mortality of hospitalized 
AMI patients showed a decline.12
A single center clinical study on the treatment of AMI 
with Danshen (Salvia miltiorrhiza) injectable powder in 
the Beijing TCM Hospital showed that the total mortality 
in the treatment group was lower than that in the control 
group. This suggests that Danshen intravenous 
preparations might be helpful for the prognosis of AMI 
patients.13 Data on 162 AMI patients in Dongfang 
Hospital of Beijing University of Chinese Medicine was 
evaluated by multi-factor analysis to determine various 
factors of mortality. The results showed that both 
angiotensin converting enzyme inhibitors (ACEI) and 
TCM herbal soup were protective factors for long-term 
prognosis of AMI patients.14 A meta-analysis by our 
group also showed that TCM intravenous preparations as 
an adjuvant treatment was useful in reducing AMI 
mortality.15 This is similar to the results from a 
retrospective study in Shanghai in the mid 1990s 16 and a 
Chinese Cardiac Study (CCS-1).17
A preliminary follow-up survey showed that TCM 
treatment was beneficial to AMI patients for their quality 
of life. A follow-up study on 115 AMI patients using the 
World Health Organization Quality of Life BREF 
(WHOQOL-BREF) showed that the scores of most 
patients were between neither poor nor good/neither 
satisfied nor dissatisfied and good in the physiological 
domain, psychological domain, social relationship 
domain, and environment domain. The total quality of 
life scores was good (47%) or not bad (46%). 
Additionally, the total health assessment scores were 
satisfied (41%) and not dissatisfied (46%).18
TCM hospitals have made continuous progress in the 
treatment standardization for AMI 
A survey in 2000 showed that reperfusion was used for 
19.6% of AMI patients in Third-grade TCM hospitals in 
the Beijing area, and thrombolytic therapy was applied 
for all the reperfusion treatments. By 2005, up to 21.9% 
of AMI patients in those hospitals used reperfusion 
therapy, and more than 50% of the cases were treated 
with interventional therapy. In 2000, no revascularization 
procedures such as interventional therapy and coronary 
artery bypass were conducted in TCM hospitals, but by 
2005, 21.9% of cases received revascularization 
treatment. Applications of angiotensin converting 
enzyme inhibitors (ACEI), beta blockers and lipid 
lowering drugs, as evidence-based treatments 
recommended in the Clinical Guidelines for AMI, 
increased greatly from 58%, 58% and 31% in 2000 to 
77%, 66% and 57% in 2005, respectively.8,11 Ten-year 
dynamic monitoring showed that the ability to perform 
reperfusion and to use drugs appropriately, as well as 
making an effort to perform the Clinical Guidelines have 
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made great progress in Third-grade TCM hospitals in the 
Beijing area. TCM intravenous preparations and 
decoctions have also been widely used.12
AMI treatment in TCM hospitals still needs to be 
improved 
The surveys also showed that TCM hospitals still had 
some problems in treating AMI, including a lack of 
standardized TCM syndrome diagnosis, a need for 
syndrome differentiation, treatment standardization, and 
clinical skills in reperfusion, and standardized drug 
treatment still needs to be further improved. 
A previous study on the regular pattern of TCM 
syndromes found that there were 74 types of TCM 
syndromes in 1124 AMI patients. Only 4 of those 
syndromes appeared in more than 5% of the total cases. 
There was no significant relationship between the 
syndrome pattern and mortality. Therefore, many types 
of syndromes being diagnosed indicates that there is a  
lack in standardization of syndrome diagnosis.19 An 
investigation on what type of treatment was given for a 
particular syndrome showed that 39% of AMI patients 
with non-blood stasis syndrome were administrated with 
TCM preparations that promoted blood circulation and 
dissolving blood stasis. Additionally, 33% of patients 
without Qi and Yin deficiency were prescribed Sheng 
Mai Yin, an herbal preparation for deficiency of both Qi
and Yin. These differences in AMI TCM treatments 
suggested that the treatment of AMI with various 
syndromes also needs to be standardized.20 Although 
there has been some progress in treatment 
standardization, reperfusion therapy used in TCM 
hospitals is still less than that in Western medicine 
hospitals. The use of drugs recommended by the “AMI 
Guidelines” is still lower in TCM hospitals than that in 
Western medicine hospitals.8,11,21,22
AMI patients in TCM hospitals have particular 
characteristics  
Our survey showed that there was a high in-hospital 
mortality rate in AMI patients in TCM hospitals in the 
Beijing area. With continuous improvement in 
reperfusion skill and standardized treatment, the 
mortality of AMI has gradually decreased in TCM 
hospitals. However, there is still a difference between 
TCM hospitals and Western medicine hospitals. The 
reason for this result needs to be determined. On the one 
hand, it suggests that further efforts should be made in 
TCM hospitals to improve the interventional therapeutic 
skill and to normalize drug therapy following the 
Clinical Guidelines. On the other hand, it suggests that 
more attention should be paid to the independent clinical 
characteristics of AMI patients in TCM hospitals. Further 
extensive data analysis will hopefully provide some 
answers. 
Compared with AMI patients in Western medicine 
hospitals during the same period, those in TCM hospitals 
had the following characteristics: they were admitted to 
hospital later; they were older when they had a heart 
attack; there were more females, there were more 
problems in their medical history, and they had more 
concomitant illnesses and complications. This 
demographic baseline data highlighted the differences 
between AMI patients in TCM hospitals and in Western 
medicine hospitals. Consequently, the therapeutic status 
and prognosis were not the same in the 2 types of 
hospitals. It is possible that there is a relationship 
between these characteristics and the relatively high 
mortality, less reperfusion treatment and fewer 
applications of some drugs recommended by the 
“Clinical Guidelines” in TCM hospitals. For example, in 
2000 and 2005, the mean age of AMI patients was 61.4 
vs 67.6 years old and 62.8 vs 69.1 years old in 
Third-grade A-Level Western medicine hospitals and 
their TCM counterpart hospitals in Beijing, respectively. 
This finding indicated that patients in TCM hospitals 
were more critical than those in Western medicine 
hospitals. TCM hospitals have a heavier burden of social 
health care. More resources and support from the 
government should be provided to these 
hospitals.10-12,21-24
Since the end of the last century, the treatment of AMI 
has focused on reperfusion, and there is a lot more 
clinical evidence for drug therapy. The “AMI Clinical 
Guidelines” form the basis for AMI standardized 
treatment. Mortality from AMI has also shown a gradual 
decrease. However, AMI is still a critical disease. We 
urgently need to determine how to reduce in-hospital 
AMI mortality. TCM treatment should be considered as 
an important alternative method. The above survey 
results suggest that Chinese medicine has potential 
advantages in reducing mortality of AMI. However, AMI 
patients in Chinese medicine hospitals have some 
particular characteristics, and they may also have a more 
critical condition than those in Western hospitals. In 
addition, TCM hospitals are still not proficient in TCM 
diagnosis and treatment standardization for AMI. 
Therefore, to ensure that TCM therapy plays a better role 
in the treatment of integrative Chinese and Western 
medicine to reduce AMI mortality, clinical research on 
TCM AMI treatment should be increased. With further
studies, more clinical evidence of TCM in the prevention 
and treatment of major diseases could also be provided to 
public health authorities and medical insurance systems. 
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